Curta

Inmaculada (Inma) Hernandez, Sean Sullivan, Emma Cousin cited by the NYT today in this article about #Medicare Price Negotiations, and how the Biden Administration would have saved $6 billion had the new prices been in effect last year. Learn more here: https://lnkd.in/gP29eA7F #Medicare #HEOR #Curta #Healtheconomics

NEW RESOURCE: Explore how the budget impact of RTM-augmented PT solutions changes under different reimbursement scenarios: https://lnkd.in/e-hkXfeK PHTI’s latest report found that some virtual MSK solutions can be substituted for in-person physical therapy (PT) to improve access and convenience. These solutions reduce healthcare spending by delivering lower cost PT and improving clinical outcomes that help avoid other, unnecessary care. To illustrate economic outcomes under different RTM reimbursement scenarios, we modeled four additional budget scenarios. This analysis finds that when RTM is used to reduce the frequency of in-person PT visits (shifting from eight visits to four) over a limited episode of care (two months), it can reduce spending. Using physical therapy assistants to monitor sessions and bill RTM produces additional savings. #DigitalHealth #HealthTech #PhysicalTherapy

Welcome Takako Shibasaki Kiener, PharmD, MSc, MPM, BScPhm to the Curta team!

In a newly published study, Curta investigators documented persistent burden of illness in heart failure with preserved or mid-range ejection fraction, despite simulated uptake of newer, guideline-recommended therapies. Check it out: https://lnkd.in/gQ4vHxSu Lucille Sun, Tori Dayer, Ryan Hansen, Sean Sullivan

Inmaculada (Inma) Hernandez, Sean Sullivan, Emma Cousin predict that as many as six oral cancer drugs could be selected for Medicare price negotiation in the next round, which begins in 2024 for prices going into effect in 2027. A number of diabetes drugs may also be targeted, including Novo Nordisk’s Ozempic. According to these policy experts, 13 drugs can be identified as eligible for negotiation. Five more can be identified as potentially eligible, but for which there is less certainty because of possible changes in Medicare spending trends. Check out the full list, with rationale, in the July 16, 2024 edition of the Pink Sheet https://lnkd.in/guedQnCv   

Sean Sullivan and colleagues just published findings from a recent multi-stakeholder roundtable exploring the critical role of #biosimilars, highlighting their potential to save billions while providing cutting-edge treatments at lower costs. Despite an estimated 💰 $23.6B 💰 in savings so far, the US biosimilar market faces challenges including price volatility, perverse economic incentives, and complex rebate structures, emphasizing the need for informed decision-making and stakeholder collaboration to achieve a sustainable biosimilar market that benefits all parties. #HEOR #Healtheconomics #Biotechnology #PharmaceuticalIndustry #Curta

Our RWE team has also recently expanded. Welcome to the Curta team Rainie (Yuhui Wu)!

Our economic modeling bandwidth has recently expanded as we welcome Iman Nourhussein to the Curta team!

Check out the latest report from #ISPOR co-authored by @Scott Ramsey on assessing RWE from EHR for HTA! The report provides guidance on data delineation and data fitness for purpose, and recommendations for HTA agencies and policymakers to improve the use of EHR-derived data over time. Learn more here: https://lnkd.in/g-ebCPZe #RWE #HEOR outcomesresearch #curtahealth #EHR #HTA #healthtechnologyassessment

🌡️ Mandatory reading for #HEOR professionals Stewing on this blog from Scott Ramsey with the Curta team this week and appreciating the candor. At the same time, I played back an investor call for a company releasing pivotal data at #EHA. The first question from investors? It was about patient-reported outcomes. The second question? About EU access strategy. These are two subject areas where HEOR shines! As such, I agree with Scott’s conclusions… “As long as the organizations that pay for these products ask for the information that HEOR provides, pharma will be obliged to supply it.” Additionally, I believe we should dispense with box-checking exercises and focus on the research that: 1️⃣ Matters to patients first 2️⃣ Drives shared decision-making Thoughts are my own. No AI tools used. #biotech #patientreportedoutcomes #marketaccess #healtheconomics #medicalaffairs